51688-75-6

Usage

Uses

Used in Pharmaceutical Industry:
4-Amino-3-ethylbenzoic acid is used as a key intermediate in the synthesis of various pharmaceutical drugs. Its presence in the molecular structure of these drugs contributes to their therapeutic properties and efficacy.
Used in Organic Chemistry Research:
4-Amino-3-ethylbenzoic acid is utilized as a research compound in organic chemistry, aiding in the exploration of new chemical reactions and the development of novel synthetic pathways.
Used in Dye Production:
4-Amino-3-ethylbenzoic acid is used as an intermediate in the production of dyes, contributing to the color properties and stability of these compounds.
Used in Material Science:
4-Amino-3-ethylbenzoic acid has potential applications in the development of new materials, where its chemical structure can be leveraged to create innovative and improved materials with specific properties.
Used in Biotechnology:
4-Amino-3-ethylbenzoic acid is employed in the field of biotechnology, where it may be used in the design of new bioactive molecules or in the development of biosensors and other biotechnological applications.

InChI:InChI=1/C9H11NO2/c1-2-6-5-7(9(11)12)3-4-8(6)10/h3-5H,2,10H2,1H3,(H,11,12)

Upstream product

• 51688-73-4 N-(4-bromo-2-ethylphenyl)acetamide 
• 34921-76-1 N-(4-cyano-2-ethyl-phenyl)-acetamide 
• 33098-65-6 2-acetamido-1-ethylbenzene 
• 103796-17-4 4-acetylamino-3-ethyl-benzoic acid 
• 105902-59-8 acetic acid-(4-acetyl-2-ethyl-anilide) 

Downstream Products

• 194809-17-1 N-(4-amino-3-ethylbenzoyl)-(αS,γR)-γ-fluoroglutamic acid α,γ-diisopropyl ester 
• 194809-19-3 N-(4-amino-3-ethylbenzoyl)-(αS,γS)-γ-fluoroglutamic acid α,γ-diisopropyl ester 
• 1314003-65-0 benzyl meptazinol para-aminometa-ethyl benzoate carbamate 
• 1314003-66-1 meptazinol para-amino-meta-ethylbenzoic acid carbamate 
• 1314003-19-4 meptazinol para-amino-meta-ethylbenzoic acid carbamate hydrochloride 
• 153304-75-7 4-amino-3-ethylbenzoic acid methyl ester 
• 1449664-81-6 N-cyano-3-ethyl-4-(methyl(1-methyl-1H-imidazo[4,5-c]pyridin-6-yl)amino)benzamide 
• 1449664-76-9 N-(2-ethyl-4-((2-methyl-1H-imidazol-1-yl)methyl)phenyl)-N,1-dimethyl-1H-imidazo[4,5-c]pyridin-6-amine 
• 1449664-75-8 1-(3-ethyl-4-(methyl(1-methyl-1H-imidazo[4,5-c]pyridin-6-yl)amino)phenyl)-2,2,2-trifluoroethanol 
• 1449664-71-4 N-(2-ethyl-4-((4-(methylsulfonyl)piperazin-1-yl)methyl)phenyl)-N,1-dimethyl-1H-imidazo[4,5-c]pyridin-6-amine 
• 1449667-77-9 N-(2-ethyl-4-((methylamino)methyl)phenyl)-N,1-dimethyl-1H-imidazo[4,5-c]pyridin-6-amine 
• 1449670-50-1 3-ethyl-4-(methyl(1-methyl-1H-imidazo[4,5-c]pyridin-6-yl)amino)benzoic acid 
• 1449667-60-0 (3-ethyl-4-(methyl(1-methyl-1H-imidazo[4,5-c]pyridin-6-yl)amino)phenyl)(4-methoxypiperidin-1-yl)methanone 
• 1449667-59-7 N-(4-((1H-imidazol-1-yl)methyl)-2-ethylphenyl)-N,1-dimethyl-1H-imidazo[4,5-c]pyridin-6-amine 

Relevant academic research and scientific papers

PRODRUGS OF OPIOIDS AND USES THEREOF

The present invention concerns prodrugs of opioid analgesics and pharmaceutical compositions containing such prodrugs. Methods for providing more consistent pain relief by increasing the bioavailability of the opioid analgesic with the aforementioned prodrugs are provided. The invention also provides for decreasing the adverse GI side effects of opioid analgesics.